Cullinan Oncology’s CLN-081 today received a Breakthrough Therapy Designation from the FDA for the treatment of locally advanced or metastatic non–small cell lung cancer (NSCLC).

Summary. Cullinan Therapeutics focuses on unaddressed or unmet needs in oncology and autoimmune conditions. In particular, Zipalertinib and CLN-978 stand out as its most promising product candidates.

--Cullinan Therapeutics, Inc., a biopharmaceutical company focused on developing modality-agnostic targeted therapies, will present new preclinical data for CLN-978, its novel CD19xCD3 T cell engager.

CLN-978 is an advanced, highly potent CD19 x CD3 bispecific T-cell engager designed to target and destroy harmful cells by binding to CD19 on B cells and CD3 on T cells. It is engineered to have a ...

The FDA granted breakthrough therapy designation to CLN-081 for treatment of certain patients with non-small cell lung cancer.The designation applies to use of the agent by patients with locally ...

CLN-978 is a type of treatment called a T-cell engager, which works by binding to the CD19, a target found on many B-cell malignancies such as B-NHL. The drug also to CD3 on T cells, thereby ...